The New AI Age

An expert view on the AI race and an investor look at how biotech is merging with traditional Chinese medicine to treat cancer.
About this Event

Rebecca Fannin invites you to join us for to our next group meeting, October 21.

5pm: Registration & Networking

5:30 Welcome and Introductory Remarks

5:40pm Tech chat on China-US AI Race

Selina Xu, China and AI Policy Lead
Office of Eric Schmidt
China technology and AI policy researcher specializing in emerging technologies, AI governance, and U.S.–China technology competition.

6:10pm Biotech Merges with Traditional Chinese Medicine

Howard Jiang, Chairman and CEO, Humanson Inc.
An AI drug discovery platform merging Traditional Chinese Medicine with Biomedical Science to treat cancer more effectively and at lower cost.

Jiang is a pioneering biotech investor with experience in capital markets, former corporate lawyer at Baker McKenzie and Troutman

Reception

Close: 7:30pm

Thanks to our host: Reed Smith LLP

(Registration required for event access)